

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association of socioeconomic status with prognosis in hypertensive patients over age 65: A cohort study in the community setting

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075188
Article Type:	Original research
Date Submitted by the Author:	28-Apr-2023
Complete List of Authors:	Martin-Fernandez, Jesus; Madrid Health Service; Rey Juan Carlos University, Department of Medical Specialties and Public Health Alonso-Safont, Tamara; Madrid Health Service, Technical Directorate of Health Information Systems, Primary Care Management; Rey Juan Carlos University Gestri, Patricia Elena Mora; Rey Juan Carlos University, Department of Medical Specialties and Public Health Polentinos Castro, Elena; Comunidad de Madrid Servicio Madrileño de Salud, Primary Care Research Unit Rodríguez-Martínez, Gemma; Madrid Health Service Bilbao, Amaia; Basurto University Hospital (Osakidetza) Cura-Gonzalez, Isabel ; Madrid Health Service, Primary Care Research Unit; Rey Juan Carlos University - Alcorcón Campus
Keywords:	Hypertension < CARDIOLOGY, Primary Care < Primary Health Care, SOCIAL MEDICINE, EPIDEMIOLOGIC STUDIES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Association of socioeconomic status with prognosis in hypertensive**
4
5 **patients over age 65: A cohort study in the community setting**
6
7
8
9
10

11
12 Authors:

13
14
15 Jesus Martín-Fernández*, PhD, MD ^{1,2,3,4}
16
17

18
19 ORCID ID: 0000-0001-9545-1549
20
21

22
23 Tamara Alonso-Safont, MD ^{5,6}
24
25

26
27 ORCID ID: 0000-0003-3837-0085
28
29

30
31 Patricia Elena Mora Gestri, MD ²
32
33

34
35 Elena Polentinos-Castro, PhD, MD ^{2,3,4,7}
36
37

38
39 ORCID ID: 0000-0001-9460-2966
40
41

42
43 Gemma Rodríguez-Martínez, NP ⁸
44
45

46
47 ORCID ID: 0009-0006-4584-7602
48
49

50
51 Amaia Bilbao-González, PhD ^{3, 9, 10,11}
52
53

54
55 ORCID ID: 0000-0002-2202-0753
56
57

58
59 Isabel del-Cura-González, PhD, MD ^{2,3,4,7}
60

ORCID ID: 0000-0002-3931-5304

- 1
2
3 1. Oeste Family and Community Care Teaching Unit, Primary Care Assistance
4
5 Management, Madrid Health Service, Madrid, Spain
6
- 7 2. Department of Medical Specialties and Public Health, Faculty of Health Sciences, Rey
8
9 Juan Carlos University, Madrid, Spain
10
- 11 3. Health Services Research Network in Chronic Diseases, REDISSEC-ISCIII, Research
12
13 Network on Chronicity, Primary Care and Health Promotion-RICAPPS (RICORS). ISCIII,
14
15 Spain
16
- 17 4. Gregorio Marañón Health Research Institute (IISGM), Madrid, Spain
18
- 19 5. Technical Directorate of Health Information Systems, Primary Care Management,
20
21 Madrid Health Service, Madrid, Spain
22
- 23 6. Doctoral student, Doctoral program in Health Sciences, Rey Juan Carlos University,
24
25 Madrid, Spain
26
- 27 7. Research Unit, Primary Care Assistance Management. Madrid Health Service, Madrid,
28
29 Spain
30
- 31 8. Infante Don Luis Health Center, Primary Care Assistance Management, Madrid Health
32
33 Service, Madrid, Spain
34
- 35 9. Osakidetza Basque Health Service, Basurto University Hospital, Research and
36
37 Innovation Unit, Bilbao, Spain
38
- 39 10. Kronikgune Health Services Research Institute, Barakaldo, Spain
40
- 41 11. Department of Medicine, Faculty of Health Sciences, University of Deusto, Bilbao, Spain
42
43
44
45
46
47
48
49

50 *Corresponding author:

51
52
53 Jesús Martín-Fernández

54
55
56 UDMAFyC Oeste. C/ Alonso Cano 8, 28933 Móstoles, Madrid

57
58
59 Email: jmfernandez@salud.madrid.org
60

ABSTRACT:

Objective:

To examine whether socioeconomic status is associated with prognosis after the diagnosis of HTN, in a population older than 65 years, in the community setting.

Design:

Retrospective cohort study.

Setting:

All the Primary Care Centres (PCC) of the Community of Madrid (n=392).

Participants:

All patients (> 65 years) with a new diagnosis of HTN (ICP-2 K86 code) in 2007- 2008, without previous kidney or cardiovascular (CV) events (n=21,754).

Interventions:

Patient records from primary care Electronic Health Records (HER) and Spanish mortality database were analyzed from January 2007 through December 2018. Sociodemographic data such as age, sex and deprivation index of the area (MEDEA index in quintiles), and characteristics, such as smoking, type 2 diabetes mellitus and hypercholesterolemia, were collected at the time of enrolment.

Primary and secondary outcome measures:

The occurrence of kidney or CV events (including mortality from these causes) and total mortality were evaluated using Cox regression.

Results:

Patients had a mean age of 73.5 (SD 6.5) years, and 63.5% were women. The median follow-up was 128.7 months (IQR: 110.6-136.7 months). There were 10,648 first kidney or cardiovascular events, including 1,508 deaths from these causes and 4,273 deaths from other causes. Adjusted for age, sex, smoking, diabetes and hypercholesterolemia, when comparing the third, fourth and last quintiles (less affluent) of the deprivation index with respect to the first quintile, the hazard of kidney or CV events increased by 14.8% (95% CI: 3.3-27.6%), 16.0% (95% CI: 6.4-26.4%) and 19.1% (95% CI: 8.9-30.2%), respectively. The deprivation index (MEDEA), was not associated with differences in adjusted total mortality.

Conclusion:

A lower socioeconomic situation was associated with the occurrence of kidney or cardiovascular events but not with total mortality in patients diagnosed with hypertension after age 65 and without previous kidney or cardiovascular events.

Keywords: hypertension; socioeconomic factors; survival; ageing; primary care

Strengths and limitations of this study

The combination of mortality regional registries and "hard events" recorded in Electronic Health Records (EHRs) can be a powerful method for monitoring outcomes.

As elderly individuals may be more likely to have stable housing situations, the identification of socioeconomic level based on area of residence may be more plausible.

1
2 In 2018, the closing date of the study, 80% of the assigned population visited their family doctor
3
4 on a PCC, which enhance study generalizability.
5
6

7
8 Some potential confounders as social support or individual socioeconomic variables have not
9
10 been included.
11

12
13 The accuracy and completeness of registries in Electronic Health Records has been only
14
15 validated for hypertension and diabetes mellitus diagnosis.
16
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

INTRODUCTION

Hypertension (HTN) is one of the most prevalent cardiovascular risk factors in the community environment, and the number of diagnoses has doubled in the past 30 years(1). HTN is associated with an excess of mortality, mainly mediated by cardiovascular (CV) disease(2,3). Although the control of hypertension through pharmacological and lifestyle measures has been shown to decrease mortality from these causes(4–7), it seems that hypertensive patients have an excess risk of cardiovascular events(8,9) and overall mortality(9–13). HTN is attributed to a large disease burden, making it responsible for the loss of 143 million disability-adjusted life years (DALYs) globally in 2015(3).

However, neither the incidence of HTN nor its prognosis are homogeneous in all social groups. Almost two decades ago, potential associations between population characteristics and individual blood pressure figures began to emerge, and these figures were influenced by circumstances such as lower educational levels(14). Social deprivation in the place of residence was significantly associated with the appearance of hypertension, even after adjusting for demographic variables and lifestyles(15). Some studies showed that the probability of suffering HTN increased by up to 30% when comparing those who had spent their childhood among the most disadvantaged social classes with people who lived in advantaged areas(16). The association between socioeconomic status and HTN seems clear, and some authors proposed that it is strongly mediated by education level(17) and that the risk of HTN increases with age(18). Subsequently, it has been shown that a lower socioeconomic situation across the lifecourse was associated with a higher incidence of HTN and that both the accumulation of socioeconomic risks and the models of social mobility with more adverse socioeconomic trajectories increased the incidence rate of HTN(19,20).

The mechanisms that explain this association are not entirely clear. It seems that unhealthy lifestyles and other risk factors (e.g., smoking and obesity), which are more frequently found in

1
2
3 subjects from lower socioeconomic classes, could partly explain these relationships(16). In
4
5 studies carried out in our environment, it has been observed that the differences in the
6
7 prevalence of hypertension according to socioeconomic factors in an older population are small,
8
9 and it is suggested that, in women, the direct effect of socioeconomic status and level of
10
11 education on hypertension are negligible. However, in men education and socioeconomic status
12
13 are related to hypertension without being mediated by the usual risk factors(21).
14
15

16
17 More recent studies show that a higher number of social vulnerabilities are associated with a
18
19 progressively greater risk of developing HTN(22). The association of a lower socioeconomic
20
21 situation and the incidence of cardiovascular disease is well described(16,23). Additionally, it is
22
23 associated with higher mortality from these causes(24) and with total mortality. Inverse
24
25 association between educational level and cardiovascular mortality has been found in our
26
27 country and it was particularly strong among women(25). Some studies relate this inequity to
28
29 worse health care received by people with low socioeconomic status(26). However, it is not clear
30
31 whether patients with HTN in a setting with universal access to healthcare suffer from these
32
33 potential differences in their prognosis associated with socioeconomic situation.
34
35

36
37 In this framework, the evidence of the association between socioeconomic status and risk
38
39 factors for cardiovascular events was stronger in older subjects(18,24). Thus, the area-level
40
41 socioeconomic status where patients live may be associated with the risk of cardiovascular
42
43 events and mortality after the diagnosis of HTN, and such an association should be evaluated in
44
45 a population aged 65 and older in the community setting.
46
47
48
49
50
51

52 **Methods**

53
54
55 This is a retrospective observational study of a cohort of all patients aged 65 years or older
56
57 diagnosed with HTN without evidence of kidney or cardiovascular disease in their Electronic
58
59 Health Record (EHR) in the Primary Care Centres (PCC) of the Community of Madrid from January
60

1
2
3 1, 2007 to January 31, 2008. We used the code ICP-2 K86, which has been previously validated
4
5 for the HTN diagnosis(27). (Figure 1).
6

7
8 The follow-up lasted until December 31, 2018, or until the moment in which the patient died or
9
10 was discharged from the health records of the Autonomous Community.
11

12 Variables collected

13
14
15 Demographic (age and sex), clinical and social variables were collected.
16

17
18 For the definition of clinical conditions, the records of the Primary Care (PC) clinical history were
19
20 used and coded according to the International Classification of Primary Care (ICPC-2)(28).
21

22
23 The following diagnoses were collected: diabetes mellitus type 2 (DM, ICPC-2 T89 and T90),
24
25 smoking history (any review that the patient smokes or diagnosis of active smoking- ICPC-2P17-
26
27 at the time or in the year prior to inclusion), and hypercholesterolemia (ICPC-2 T93). The
28
29 response variables were kidney or CV events, death from any cause and kidney or CV death. The
30
31 International Classification of Diseases 10th edition (ICD-10) was used to study the causes of
32
33 mortality(29).
34
35

36
37
38 In the follow-up, it was considered that there was a kidney or cardiovascular event at the time
39
40 that one of the following diagnoses appeared: chronic kidney disease (ICPC-2 U99.1), ischaemic
41
42 heart disease (acute myocardial infarction- ICPC-2 K75, angina- ICPC-2K74-, cardiac ischaemia,
43
44 chronic - ICPC-2 K76, cerebrovascular disease- ICPC-2 K90, peripheral arterial disease- ICPC-2
45
46 K92, urinary microalbuminuria (yes/no), defined as a urine albumin/creatinine ratio greater than
47
48 30, existence of proteinuria (yes/no) defined as the presence of 300 mg/dl of protein in urine in
49
50 at least two consecutive samples in the absence of concomitant disease.
51

52
53
54 The International Classification of Diseases 10th edition (ICD-10) was used to study the causes
55
56 of mortality(29). Deaths due to chronic kidney disease (ICD10: N18), cerebrovascular accident
57
58 (ICD10: G46; I60-I69), ischaemic heart disease (ICD10: I20-I25), heart failure (ICD10: I50) and
59
60

1
2
3 peripheral arterial disease (ICD10: I70, I71, I72, I74), were classified as kidney/cardiovascular
4
5 mortality.

6
7
8 As a classification variable of the social situation of the area, the deprivation index assigned to
9
10 each census tract in the MEDEA project was used, calculated from indicators related to work
11
12 (unemployment, manual and casual workers) and education (total insufficient education among
13
14 young people). This index allows the detection of small areas of large cities with an unfavourable
15
16 socioeconomic situation and is related to general mortality(30). The index was categorized into
17
18 quintiles, with the first being the most favoured and the fifth the least favoured.

19
20
21 The data sources linked using a matching algorithm were the EHR of PC and the registry of
22
23 mortality by specific cause of the National Institute of Statistics. This study followed the
24
25 guidelines for cohort studies, described in the Strengthening the Reporting of Observational
26
27 Studies in Epidemiology (STROBE) reporting guideline and the RECORD statement.

31 Analysis

32
33
34 The database construction involved several steps to enhance data quality (see figure 1).

35
36
37 The distribution of the independent variables of the subject, the mean area of residence and
38
39 the follow-up times were described.

40
41
42 Cox proportional hazards models were adjusted to study the risks associated with the context
43
44 in which the subjects lived(31). The proportional hazards assumption in a Cox proportional
45
46 hazards model was not met when using conventional tests, but hazard ratios over time were
47
48 assessed and were found to be stable enough to proceed with the analysis. Additionally, other
49
50 concerns such as influential outliers, missing data, or significant model misspecification were
51
52 considered. The 95% confidence intervals for the Cox regression coefficients were estimated
53
54 using bootstrap resampling. This approach has been suggested in large sample sizes or complex
55
56 clinical scenarios(32).
57
58
59
60

1
2
3 The models were adjusted for the demographic and clinical variables of the patients.
4
5 Independent models were constructed for the occurrence of kidney or cardiovascular events,
6
7 including mortality from these causes, and for total mortality. The final models were also built
8
9 separately for men and women. We estimated an expected size for the cohort about 20,000
10
11 subjects. It would allow finding differences in event occurrences of 2% at 10 years in each of the
12
13 quintiles of the deprivation index (between 12% and 20%) even in the presence of very high
14
15 variance inflation factors(33).
16

17 18 19 Patient involvement

20
21 Patients with hypertension diagnosis were not involved in setting the research question or the
22
23 outcome measures. We will use these results in an ongoing research which aims to study how
24
25 hypertension impact on health perception by means of focal groups.
26
27

28 29 **Results**

30
31
32 We included 21,754 patients over age 65 with new diagnoses of uncomplicated HTN in 392
33
34 centres and clinics: 12,334 in 2007 and 9,419 in 2008 (Figure 1).
35

36
37 Table 1 shows the characteristics of the studied cohort, in which women predominate (63.5%),
38
39 with a mean age at inclusion of 73.5 years (SD 6.5 years, range 65-101 years; median 72 years,
40
41 interquartile range 68-78 years). The prevalence of smokers is lower than in the general
42
43 population, while the levels of DM and hypercholesterolemia are high.
44
45

46
47 The median follow-up of the cohort was 128.7 months (IQR 110.6-136.7 months).
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of the studied cohort (n = 21,754)

Medea Index	1 st Q	2 nd Q	3 rd Q	4 th Q	5 th Q	Total*
Age						
65 to 74 years	2,562 (57.2%)	2,571 (59.2%)	2,655 (62.6%)	2,828 (64.7%)	2,797 (64.9%)	13,413 (61.7%)
75 to 84 years	1,503 (33.5%)	1,433 (33.0%)	1,301 (30.7%)	1,302 (29.8%)	1,304 (30.3%)	6,843 (31.5%)
≥ 85	417 (9.3%)	340 (7.8%)	283 (6.7%)	240 (5.5%)	207 (4.8%)	1,487 (6.8%)
Median (IQR)	73 (69-79)	73 (68-78)	72 (68-77)	72 (68-77)	72 (68-77)	72 (68-78)
Woman	3,000 (63.9%)	2,811 (64.7%)	2,666 (62.9%)	2,726 (62.4%)	2,598 (60.3%)	13,801 (63.5%)
Smokers	296 (6.6%)	272 (6.3%)	254 (6.0%)	268 (6.1%)	295 (6.9%)	1,385 (6.4%)
Diabetes mellitus	518 (11.6%)	569 (13.1%)	585 (13.8%)	685 (15.8%)	673 (15.6%)	3,030 (13.9%)
Hypercholesterolemia	1,221 (27.2%)	1,150 (26.51%)	1,168 (27.6%)	1,264 (28.9%)	1,240 (28.8%)	6043 (27.8%)

*It was not possible to assign the MEDEA index to 11 subjects.

Q: quintile

IQR: Interquartile range

Occurrence of kidney or CV events included death from these causes

During follow-up, 10,648 first kidney/CV events occurred (including 1,508 deaths due to these causes without a previous event). A total of 1,937,655 person-months were observed, and the incidence rate of these events was 54/10,000 person-months. The median time of occurrence of the event was 62.6 months (IQR 33.6-92.3 months).

Table 2 shows the results of the best model explaining the association between the deprivation index and the occurrence of kidney/CV events (including death from these causes).

Table 2. Cox model for kidney or cardiovascular events, including mortality from these causes, adjusted for the covariates shown.

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	1,767	1,686- 1,851	<0.001
≥ 85 vs. 65-74 years	2,980	2,731- 3,25	<0.001
Female vs. male	0,966	0,927- 1,006	0.097
Diabetes mellitus	1,357	1,283- 1,435	<0.001
Baseline smoking	1,208	1,122- 1,301	<0.001
Hypercholesterolemia	1,066	1,023- 1,111	0.002
Socioeconomic group		0- 0	<0.001
2nd vs. 1st quintile	1,009	0,916- 1,112	0.849
3rd vs. 1st quintile	1,148	1,033- 1,276	0.010
4th vs. 1st quintile	1,160	1,064- 1,264	0.001
5th vs. 1st quintile	1,191	1,089- 1,302	<0.001
Included subjects = 21,743, number of clusters (centres): 392, Number of events: 10,648			

HR = Hazard ratio; CI = Confidence interval

Adjusted for age, sex, smoking, diabetes mellitus and hypercholesterolemia, an association is observed between greater deprivation and the greater occurrence of kidney or CV events, starting from the third quintile of the MEDEA Index. This association increases slightly in intensity as the deprivation index worsens; the more unfavourable this index is, the stronger the association.

Figure 2 shows the cumulative hazard function by quintiles adjusted for the variables (at means) shown in the model in Table 2. The second quintile is not clearly different from the first, but there is an evident increase in cumulative hazard in the third, fourth and fifth quintiles, with respect to the first, after adjusting for the aforementioned variables.

The best model was run separately for men and women but no significant difference were found with the overall model (see Additional file 1, Supplementary Tables).

Occurrence of mortality from any cause

During follow-up, 5,781 deaths occurred from any cause, 1,508 deaths from kidney/CV causes and 4,273 from other causes. A total of 2,513,273 person-months was observed, and the incidence rate of these events was 23/10,000 person-months. The median time to death in those who died during the study period was 85.4 months (IQR 55.4–109.5 months).

Table 3 shows the model that studies the association between the deprivation index and mortality.

In this case, there is no association between this index and all-cause mortality. Regarding the adjustment variables, the association of age with mortality was very strong; female sex was associated with lower mortality, smoking and DM were associated with higher mortality. Hypercholesterolemia and total mortality appeared to be inversely related in this model.

Again, the best model for total mortality was run separately for men and women and no relevant differences were found with the overall model (see Additional file 1, Supplementary Tables)

Table 3. Cox model to explain all-cause mortality, adjusted for the covariates shown.

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	3.446	3.255- 3.649	<0.001
≥ 85 vs. 65-74 years	13.115	12.214- 14.083	<0.001
Female vs. male	0.695	0.656- 0.736	<0.001
Diabetes mellitus	1.319	1.223- 1.422	<0.001
Baseline smoking	1.418	1.269- 1.583	<0.001
Hypercholesterolemia	0.782	0.731- 0.837	<0.001
Socioeconomic group			0.391
2nd vs. 1st quintile	0.942	0.82- 1.081	0.395
3rd vs. 1st quintile	0.913	0.798- 1.044	0.183
4th vs. 1st quintile	0.866	0.781- 1.006	0.062
5th vs. 1st quintile	0.952	0.846- 1.072	0.420
Included subjects = 21,743 Number of clusters (centres): 392, number of events: 5,781			

HR = Hazard ratio; CI = Confidence interval

Discussion

The deprivation index of the area in which one lives is associated with an increase in kidney/CV events in hypertensive patients diagnosed after age 65 and without previous cardiovascular history, in follow-up in the community environment for more than 10 years. This association remained after adjusting for other potential demographic and metabolic risk factors, such as diabetes or hypercholesterolemia, or lifestyles indicators, such as smoking. This association was not found when mortality from all causes was studied. It should also be noted that no gender differences were found when studying the aforementioned relationships between socioeconomic status and prognosis in older patients with hypertension.

In this study, an increased hazard of almost 20% of kidney/CV events (including death due to these causes) was found in patients residing in areas in the least affluent quintile compared to those who inhabited the most favoured areas. The association between the incidence of HTN

1
2
3 and social group is already known(15,16), also in the elderly(21). In addition, an association
4
5 between a lower socioeconomic situation and an increased risk of cardiovascular and total
6
7 mortality was found, and it seems that the factors that mediated this association had to do
8
9 mainly with habits and inflammatory markers rather than with psychosocial risk(24). Other
10
11 authors support that the role of conventional risk factors might be minor in explaining
12
13 relationship between social and psychological factors and cardiovascular disease(34).
14
15 Moreover, other social situations such as being unmarried or not cohabiting have been
16
17 identified as important additional risk factors for cardiovascular and total mortality(35).The
18
19 association between cardiovascular mortality and socioeconomic characteristics has been
20
21 described generically in our environment(25,36). However, there has been a sharp decline in
22
23 cardiovascular mortality rates in the most disadvantaged socioeconomic groups in recent
24
25 decades, which is attributed to better access to preventive activities and health care(37). The
26
27 study of the association between socioeconomic status and mortality in hypertensive patients
28
29 has been recently reported at the individual level, but it was not evident when the
30
31 socioeconomic status of the area was studied(22). The association between socioeconomic
32
33 status and mortality when HTN is combined with another cardiovascular risk factor, such as DM,
34
35 is much stronger. Increases of almost four times the risk of mortality have been reported when
36
37 DM and HTN are associated with low income levels(38), our results also go in the same direction.
38
39 Furthermore, we have extended the understanding to evaluate the association of the
40
41 socioeconomic level of the area with kidney or CV events, adjusted for the potential effect of
42
43 other classic cardiovascular risk factors.
44
45
46
47
48
49

50 We found no apparent relationship between the socioeconomic status of the area and total
51
52 mortality in newly diagnosed hypertensive patients over age 65 years. When the relationship
53
54 between socioeconomic status and total mortality in older patients is studied, the differences in
55
56 the Spanish population are lower than in the rest of Europe(39). These differences with respect
57
58 to patterns of other countries have been explained by lifestyles and the existence of stronger
59
60

1
2
3 social networks, regardless of social class. It has been mentioned how social support can be a
4
5 protective factor against cardiovascular mortality in older people(40). In our country, individuals
6
7 over age 65 who lived in provinces with the most adverse socioeconomic context had the highest
8
9 mortality from cardiovascular diseases and the lowest mortality from cancer and external
10
11 causes(41). This may mean that the association between socioeconomic status and total
12
13 mortality is not as strong as expected. In general, the trend of the past two decades is that
14
15 inequalities in total mortality are reduced in all European countries and, especially, in Spain. This
16
17 change is attributed more to improvements in lifestyle and access to preventive activities than
18
19 to policies aimed at reducing health inequalities(42). A previous study conducted in the same
20
21 region as ours, reported a differential use of more intensive PC services in those subjects with
22
23 lower economic situations(43). This could indicate that there are no major problems with
24
25 accessibility to health care and preventive activities and would partly explain why no association
26
27 was found between the socioeconomic status of the area and total mortality in this group of
28
29 patients.
30
31
32
33

34
35 One element to assess is the measurement of the socioeconomic situation. There are multiple
36
37 characteristics that can define the socioeconomic situation, and this can be observed from a
38
39 multidimensional perspective(44). Many of the studies mentioned use indicators of individual
40
41 socioeconomic position(22,24,38). Others use the socioeconomic status of the area and
42
43 evaluate its relationship with survival after a cardiovascular event(45). In fact, the deprivation
44
45 of the area has been shown to be a better predictor than the individual socioeconomic situation
46
47 when studying the occurrence of cardiovascular events(46). In this case, an aggregate indicator,
48
49 the MEDEA index, was chosen because of its availability, multiple approaches and ability to
50
51 correctly capture the social situation and be useful in the study of inequality(30).
52
53
54
55
56
57
58
59
60

1
2
3 This study was subjected to several potential limitations. Given its design, causal inferences
4 cannot be made, individual socioeconomic variables have not been included, other variables
5 such as marital status have not been considered, underlying diseases have not been controlled,
6
7 and there are limitations inherent to studies that use registries not designed for research.
8
9 Among its potential strengths, this study points out that the monitoring of the outcomes could
10
11 be done exhaustively by combining two independent sources. Since the study population is
12
13 elderly, the identification of the socioeconomic level with that of the area of residence may be
14
15 more plausible. Also, the generalizability of the results is good enough, as accessibility to the
16
17 health system, specifically to the PC doctor, is very high in our environment. In 2018, the closing
18
19 date of the study, 80% of the assigned population visited their family doctor on a PCC(47).
20
21
22
23
24

25
26 The implications of the results discussed are clear. As has been suggested, to reduce the burden
27
28 of disease derived from HTN, strategies are needed to accelerate the socioeconomic
29
30 improvements of the most vulnerable population and the development of environments that
31
32 promote health(48). If primary care, which provides greater accessibility to the health system,
33
34 and the implementation of preventive strategies are responsible for the reduction of
35
36 socioeconomic differences in mortality, enhancing access to care through investment and
37
38 organizational resources is necessary. Public health policies that affect healthy behaviours
39
40 should also be reinforced.
41
42
43

44 **Conclusion**

45
46
47 The deprivation index of the area in which one lives is associated with an increase in kidney or
48
49 CV events in hypertensive patients diagnosed after age 65 and without previous cardiovascular
50
51 history, but no association was found when mortality from all causes was studied.
52
53

54
55 The role of access to health care and preventive activities should be established, as well as future
56
57 research on the lack of association between socioeconomic status and total mortality.
58
59
60

Declarations

Ethics approval and consent to participate

Authorization was obtained from the Ethics Committee at the Alcorcon Foundation University Teaching Hospital (18/115).

The study was carried out in accordance with the guidelines of good research practices, the principles of the Declaration of Helsinki (Fortaleza 2013), the provisions of Organic Law 3/2018 of December 5 for the Protection of Personal Data and guarantee of digital rights, and Law 14/2007 on Biomedical Research. Once all the databases were related, the data were dissociated, eliminating any potential identifiers.

The protocol approved by the Ethics Committee (see above) did not include a request for informed consent because the data handled by the researchers were dissociated and made patient identification impossible.

Consent for publication

Not applicable (see above)

Availability of data and materials

All data analysed during this study are included in this published article as a supplementary information file (Additional file 2, Raw data).

Competing interests

The authors declare no conflicts of interest.

Funding

The study was funded by the Carlos III Health Institute (ISCIII, PI1800370) and co-financed by the European Union.

Authors' contributions

Conceived and designed the experiments: JMF, TAS, EPC, GRM, ABG.

Performed the experiments: JMF, TAS, EPC.

Analysed the data: JMF, TAS, PMG.

Discussed the results: JMF, TAS, PMG, EPC, GRM, ICG, ABG.

Wrote the manuscript: JMF, PMG, ICG.

Revised and approved the manuscript: JMF, TAS, PMG, EPC, GRM, ICG, ABG.

All authors read and approved the final manuscript.

References

1. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet*. 2021;398(10304):957–80.
2. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. *BMJ*. 1998 Jul 18;317(7152):167–71.
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015. *JAMA*. 2017;317(2):165–82.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338(7705):1245.
5. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. *Int J Cardiol*. 2014 Sep;176(1):219–26.
6. Bundy J, Li C, Studlik P, Bu X, Kelly T, Mills KT, et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality A Systematic Review and Network Meta-analysis. *JAMA Cardiol*. 2017;2(7):775–81.
7. Yun D, Lee H, Choi W, Chang H, Son D, Lee J. Association of optimal blood pressure with mortality in patients taking antihypertensive medications. *J Clin Hypertens*. 2020 Nov 20;22(11):2035–43.
8. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension - A prospective cohort study over three decades. *J Intern Med*. 2005;257(6):496–502.
9. Martín-Fernández J, Alonso-Safont T, Polentinos-Castro E, Esteban-Vasallo MD, Ariza-Cardiel G, González-Anglada MI, et al. Impact of hypertension diagnosis on morbidity and mortality: a retrospective cohort study in primary care. *BMC Prim Care*. 2023 Mar 23;24(1):79.

10. Sepanlou SG, Sharafkhan M, Poustchi H, Malekzadeh MM, Etemadi A, Khademi H, et al. Hypertension and mortality in the Golestan Cohort Study: A prospective study of 50000 adults in Iran. Vol. 30, *J Hum Hypertens*. Macmillan Publishers Limited; 2016. p. 260–7.
11. da Silva TLN, Klein CH, Nogueira A da R, Salis LHA, de Souza E Silva NA, Bloch KV. Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de Janeiro - Brazil - 1991-2009. *BMC Public Health*. 2015;15:623.
12. Lawlor DA, Kim L, Morris R, Amuzu A, Whincup P, Ebrahim S. Survival with treated and well-controlled blood pressure: Findings from a prospective cohort study. *PLoS One*. 2011;6(4).
13. Park S, Han K, Lee S, Kim Y, Lee Y, Kang MW, et al. Cardiovascular or mortality risk of controlled hypertension and importance of physical activity. *Heart*. 2021 Sep;107(18):1472–9.
14. Merlo J, Asplund K, Lynch J, Rastam L, Dobson A. Population Effects on Individual Systolic Blood Pressure: A Multilevel Analysis of the World Health Organization MONICA Project. *Am J Epidemiol*. 2004 Jun 15;159(12):1168–79.
15. Matheson FI, White HL, Moineddin R, Dunn JR, Glazier RH. Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis. *J Epidemiol Community Heal*. 2010 Aug 1;64(8):705–13.
16. Lawlor DA, Ebrahim S, Smith GD. Adverse socioeconomic position across the lifecourse increases coronary heart disease risk cumulatively: Findings from the British women's heart and health study. *J Epidemiol Community Health*. 2005;59(9):785–93.
17. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension. *J Hypertens*. 2015 Feb;33(2):221–9.
18. López-González ÁA, Bennasar-Veny M, Tauler P, Aguilo A, Tomàs-Salvà M, Yáñez A. Desigualdades socioeconómicas y diferencias según sexo y edad en los factores de riesgo cardiovascular. *Gac Sanit*. 2015 Jan;29(1):27–36.
19. Lopes JAS, Giatti L, Griep RH, Lopes AADS, Matos SMA, Chor D, et al. Life Course Socioeconomic Position, Intergenerational Social Mobility, and Hypertension Incidence in ELSA-Brasil. *Am J Hypertens*. 2021 Aug 9;34(8):801–9.
20. Duarte C d. P, Wannier SR, Cohen AK, Glymour MM, Ream RK, Yen IH, et al. Lifecourse Educational Trajectories and Hypertension in Midlife: An Application of Sequence

- 1
2
3 Analysis. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2022;77(2):383–91.
4
5 21. Regidor E, Gutiérrez-Fisac JL, Banegas JR, Domínguez V, Rodríguez-Artalejo F.
6 Association of adult socioeconomic position with hypertension in older people. *J*
7 *Epidemiol Community Health*. 2006 Jan 1;60(1):74–80.
8
9
10 22. King JB, Pinheiro LC, Ringel JB, Bress AP, Shimbo D, Muntner P, et al. Multiple social
11 vulnerabilities to health disparities and hypertension and death in the regards study.
12 *Hypertension*. 2022;79(1):196–206.
13
14 23. Woodward M, Peters SAE, Batty GD, Ueshima H, Woo J, Giles GG, et al. Socioeconomic
15 status in relation to cardiovascular disease and cause-specific mortality: a comparison
16 of Asian and Australasian populations in a pooled analysis. *BMJ Open*. 2015 Mar
17 17;5(3):e006408–e006408.
18
19 24. Stringhini S, Zaninotto P, Kumari M, Kivimäki M, Lassale C, Batty GD. Socio-economic
20 trajectories and cardiovascular disease mortality in older people: The English
21 Longitudinal Study of Ageing. *Int J Epidemiol*. 2018;47(1):36–46.
22
23 25. Haeberer M, León-Gómez I, Pérez-Gómez B, Tellez-Plaza M, Rodríguez-Artalejo F, Galán
24 I. Social inequalities in cardiovascular mortality in Spain from an intersectional
25 perspective. *Rev Española Cardiol (English Ed)*. 2020 Apr;73(4):282–9.
26
27 26. Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF,
28 et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-
29 income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE)
30 study. *Lancet Glob Heal*. 2019 Jun;7(6):e748–60.
31
32 27. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, Soto-Díaz S, Fuentes-
33 Rodríguez CY, Abánades-Herranz JC, et al. Validation of diabetes mellitus and
34 hypertension diagnosis in computerized medical records in primary health care. *BMC*
35 *Med Res Methodol*. 2011 Dec 28;11(1):146.
36
37 28. World Health Organization (WHO). International Classification of Primary Care, -ICPC-2.
38 World Health Organization; 2009.
39
40 29. World Health Organization (WHO). ICD-10: international statistical classification of
41 diseases and related health problems: tenth revision. World Health Organization; 2004.
42
43 30. Domínguez-Berjón MF, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarín MI, et al.
44 Construcción de un índice de privación a partir de datos censales en grandes ciudades
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- españolas (Proyecto MEDEA). *Gac Sanit.* 2008;22(3):179–87.
31. Christensen E. Multivariate survival analysis using Cox's regression model. *Hepatology.* 1987 Nov;7(6):1346–58.
32. Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? *JAMA.* 2020 Apr 14;323(14):1401.
33. Ahnn S, Anderson SJ. Sample size determination for comparing more than two survival distributions. *Stat Med.* 1995 Oct 30;14(20):2273–82.
34. Tillmann T, Pikhart H, Peasey A, Kubinova R, Pajak A, Tamosiunas A, et al. Psychosocial and socioeconomic determinants of cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. Rahimi K, editor. *PLOS Med.* 2017 Dec 6;14(12):e1002459.
35. Stringhini S, Berkman L, Dugravot A, Ferrie JE, Marmot M, Kivimaki M, et al. Socioeconomic Status, Structural and Functional Measures of Social Support, and Mortality. *Am J Epidemiol.* 2012 Jun 15;175(12):1275–83.
36. Domínguez-Berjón MF, Gandarillas A, Segura Del Pozo J, Zorrilla B, Soto MJ, López L, et al. Census tract socioeconomic and physical environment and cardiovascular mortality in the Region of Madrid (Spain). *J Epidemiol Community Health.* 2010;64(12):1086–93.
37. Di Girolamo C, Nusselder WJ, Bopp M, Brønnum-Hansen H, Costa G, Kovács K, et al. Progress in reducing inequalities in cardiovascular disease mortality in Europe. *Heart.* 2020 Jan;106(1):40–9.
38. Andersson T, Pikkemaat M, Schiöler L, Hjerpe P, Carlsson AC, Wändell P, et al. The impact of diabetes, education and income on mortality and cardiovascular events in hypertensive patients: A cohort study from the Swedish Primary Care Cardiovascular Database (SPCCD). Pizzi C, editor. *PLoS One.* 2020 Aug 3;15(8):e0237107.
39. Regidor E, Kunst AE, Rodríguez-Artalejo F, Mackenbach JP. Small socio-economic differences in mortality in Spanish older people. *Eur J Public Health.* 2012 Feb;22(1):80–5.
40. Ramsay S, Ebrahim S, Whincup P, Papacosta O, Morris R, Lennon L, et al. Social Engagement and the Risk of Cardiovascular Disease Mortality: Results of a Prospective Population-Based Study of Older Men. *Ann Epidemiol.* 2008 Jun;18(6):476–83.
41. Regidor E, Vallejo F, Reques L, Cea L, Miqueleiz E, Barrio G. Area-level socioeconomic

- 1
2
3 context, total mortality and cause-specific mortality in Spain: Heterogeneous findings
4 depending on the level of geographic aggregation. *Soc Sci Med*. 2015 Sep;141:142–50.
5
6
7 42. Mackenbach JP, Kulháňová I, Artnik B, Bopp M, Borrell C, Clemens T, et al. Changes in
8 mortality inequalities over two decades: register based study of European countries.
9 *BMJ*. 2016 Apr 11;353:i1732.
10
11
12 43. Martín-Fernández J, Gómez-Gascón T, Cura-González MI Del, Tomás-García N, Vargas-
13 Machuca C, Rodríguez-Martínez G. [Quality of life related to health as a factor
14 explaining the use of family medical consultation: a study on the behavioral model]. *Rev*
15 *Esp Salud Publica*. 2010;84(3):293–19.
16
17
18 44. Havranek EP, Mujahid MS, Barr DA, Blair I V., Cohen MS, Cruz-Flores S, et al. Social
19 determinants of risk and outcomes for cardiovascular disease: A scientific statement
20 from the American Heart Association. *Circulation*. 2015;132(9):873–98.
21
22
23 45. Chaix B, Rosvall M, Merlo J. Neighborhood Socioeconomic Deprivation and Residential
24 Instability. *Epidemiology*. 2007 Jan;18(1):104–11.
25
26
27 46. Leyland AH. Socioeconomic gradients in the prevalence of cardiovascular disease in
28 Scotland: The roles of composition and context. *J Epidemiol Community Health*.
29 2005;59(9):799–803.
30
31
32 47. Servicio Madrileño de Salud. Consejería de Sanidad. Indicadores de Atención Primaria
33 [Internet]. Observatorio de resultados del Servicio Madrileño de Salud. 2021. Available
34 from:
35 <http://observatorioresultados.sanidadmadrid.org/AtencionPrimariaFicha.aspx?ID=73>
36
37
38 48. O'Brien E. The Lancet Commission on hypertension: Addressing the global burden of
39 raised blood pressure on current and future generations. *J Clin Hypertens*.
40 2017;19(6):564–8.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Cohort generation flow diagram**
4
5
6
7
8
9
10

11
12 EHR: Electronic Health Record; CIBELES: Centre of strategic basic information for health
13 environments
14

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

1
2
3 **Figure 2. Cumulative hazard function of suffering a kidney or cardiovascular event (including**
4 **death from these causes) according to MEDEA quintile, adjusted for age, sex, presence of**
5 **diabetes mellitus, smoking and hypercholesterolemia (model in table 2).**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Supplementary tables

Table 1. Cox model for kidney and cardiovascular events, including mortality from these causes, adjusted for the covariates shown (only men)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	1.656	1.542- 1.779	<0.001
≥ 85 vs. 65-74 years	2.639	2.262- 3.078	<0.001
Diabetes mellitus	1.335	1.234- 1.445	<0.001
Baseline smoking	1.219	1.111- 1.337	<0.001
Hypercholesterolemia	1.072	0.994- 1.157	0.065
Socioeconomic group			0.018
2nd vs. 1st quintile	1.082	0.958- 1.222	0.206
3rd vs. 1st quintile	1.141	1.007- 1.294	0.039
4th vs. 1st quintile	1.142	1.019- 1.28	0.022
5th vs. 1st quintile	1.213	1.078- 1.366	0.001
Characteristics of the model: No. of subjects = 7,942, number of clusters (centres): 392, Number of events: 3,852			

Table 2. Cox model for kidney and cardiovascular events, including mortality from these causes, adjusted for the covariates shown (only women)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	1.830	1.728- 1.937	<0.001
≥ 85 vs. 65-74 years	3.121	2.816- 3.459	<0.001
Diabetes mellitus	1.372	1.281- 1.469	<0.001
Baseline smoking	1.161	1.015- 1.327	0.029
Hypercholesterolemia	1.064	1.012- 1.119	0.018
Socioeconomic group			<0.001
2nd vs. 1st quintile	0.972	0.873- 1.082	0.601
3rd vs. 1st quintile	1.151	1.027- 1.29	0.016
4th vs. 1st quintile	1.171	1.062- 1.291	0.001
5th vs. 1st quintile	1.176	1.06- 1.304	0.002
Characteristics of the model: No. of subjects = 13,801, number of clusters (centres): 392, Number of events: 6,791.			

Table 3. Cox model for total mortality, adjusted for the covariates shown (only men)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	2.897	2.657- 3.159	<0.001
≥ 85 vs. 65-74 years	9.861	8.648- 1.125	<0.001
Diabetes mellitus	1.264	1.127- 1.419	<0.001
Baseline smoking	1.380	1.221- 1.56	<0.001
Hypercholesterolemia	0.791	0.713- 0.877	<0.001
Socioeconomic group			0.462
2nd vs. 1st quintile	0.892	0.755- 1.053	0.177
3rd vs. 1st quintile	0.919	0.783- 1.079	0.304
4th vs. 1st quintile	0.915	0.78- 1.073	0.273
5th vs. 1st quintile	0.994	0.854- 1.158	0.942
Characteristics of the model: No. of subjects = 7,942, number of clusters (centres): 392, Number of events: 2,349.			

Table 4. Cox model for total mortality, adjusted for the covariates shown (only women)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	4.056	3.723- 4.419	<0.001
≥ 85 vs. 65-74 years	15.814	14.433- 17.327	<0.001
Diabetes mellitus	1.361	1.234- 1.501	<0.001
Baseline smoking	1.378	1.133- 1.676	0.001
Hypercholesterolemia	0.786	0.726- 0.85	<0.001
Socioeconomic group			0.388
2nd vs. 1st quintile	0.982	0.838- 1.149	0.819
3rd vs. 1st quintile	0.909	0.776- 1.065	0.237
4th vs. 1st quintile	0.872	0.749- 1.016	0.079
5th vs. 1st quintile	0.917	0.799- 1.052	0.217
Characteristics of the model: No. of subjects = 13,801, number of clusters (centres): 392, Number of events: 3,429.			

We agree with the reviewer that these calculations may no longer be necessary. The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1 Page 3-4	RECORD 1.1: The types of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and time and place within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 3 Page 3 Page 3
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6-7		
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 7		
Study Design	4	Present key elements of study design early in the paper	Page 7		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 7-8		

086/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (A.B.E.S.). All rights reserved. No reuse allowed without permission.

<p>Participants</p>	<p>6</p>	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	<p>Page 7-8</p>	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation is conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, computer use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Page 8 & Figure 1</p> <p>Page 8</p> <p>Page 8-9 & Figure 1</p>
<p>Variables</p>	<p>7</p>	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>	<p>Page 8-9</p>	<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.</p>	<p>Page 8-9</p>
<p>Data sources/ measurement</p>	<p>8</p>	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p>	<p>Page 8-9</p>		

Bias	9	Describe any efforts to address potential sources of bias	Page 9-10		
Study size	10	Explain how the study size was arrived at	Page 10		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Page 9-10		
Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>	Page 9-10		
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Page 9

08/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025
 Engagemment Supérieur (ABES) .
 Agence Bibliographique de l'Enseignement Supérieur
 selected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur et de la Recherche et de l'Innovation. All rights reserved. No reuse allowed without permission.

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Page 9
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Page 8-9
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	(a) Page 10 Non applicable (c) Figure 1	RECORD 13.1: Describe in detail the selection of the persons included in the study (i.e., study population selection) including filtering based on data quality, data availability, and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Figure 1
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (e.g., average and total amount)	(a) Page 10-11, Table 1 Non applicable (c) Page 10		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time	Page 11-14 Table 2, 3 Figure 2		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p><i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i> - Report numbers of outcome events or summary measures</p>			
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p>	Page 11-13 Table 2,3, Figure 2		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses	Non applicable		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Page 14		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 17	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Page 17

36/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
 used by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1 2 3 4 5 6 7	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 16-17		
8 9 10 11	Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 17		
12	Other Information					
13 14 15 16 17 18	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 19		
19 20 21 22 23 24	Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Additional file 2

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langen SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

86/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (A.B.E.S.) - Université de Lille. All rights reserved.

BMJ Open

Association of socioeconomic status with prognosis in hypertensive patients over age 65: A cohort study in the community setting

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075188.R1
Article Type:	Original research
Date Submitted by the Author:	10-Nov-2023
Complete List of Authors:	Martin-Fernandez, Jesus; Comunidad de Madrid Servicio Madrileño de Salud, UDM Atención Familiar y comunitaria Oeste; Universidad Rey Juan Carlos - Campus de Alcorcon, Departamento de Especialidades Médicas y Salud Pública Alonso-Safont, Tamara; Comunidad de Madrid Servicio Madrileño de Salud, Dirección Técnica de Sistemas de Información; Universidad Rey Juan Carlos - Campus de Alcorcon Gestri, Patricia Elena Mora; Universidad Rey Juan Carlos Polentinos Castro, Elena; Comunidad de Madrid Servicio Madrileño de Salud, Unidad de Investigación de Atención Primaria; Universidad Rey Juan Carlos - Campus de Alcorcon Rodríguez-Martínez, Gemma; Comunidad de Madrid Servicio Madrileño de Salud, Consultorio Infante Don Luis Bilbao, Amaia; Hospital Universitario Basurto; Kronikgune Cura-Gonzalez, Isabel ; Comunidad de Madrid Servicio Madrileño de Salud, Unidad de Investigación en Atención Primaria; Universidad Rey Juan Carlos - Campus de Alcorcon, Departamento de Especialidades Médicas y Salud Pública
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Public health
Keywords:	Hypertension < CARDIOLOGY, Primary Care < Primary Health Care, SOCIAL MEDICINE, EPIDEMIOLOGIC STUDIES, Aging

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Association of socioeconomic status with prognosis in hypertensive**
4
5 **patients over age 65: A cohort study in the community setting**
6
7
8
9
10

11
12 Authors:

13
14
15 Jesus Martín-Fernández*, PhD, MD ^{1,2,3,4}
16
17

18
19 ORCID ID: 0000-0001-9545-1549
20
21

22
23 Tamara Alonso-Safont, MD ^{5,6}
24
25

26
27 ORCID ID: 0000-0003-3837-0085
28
29

30
31 Patricia Elena Gestri-Mora, MD ²
32
33

34
35 Elena Polentinos-Castro, PhD, MD ^{2,3,4,7}
36
37

38
39 ORCID ID: 0000-0001-9460-2966
40
41

42
43 Gemma Rodríguez-Martínez, NP ⁸
44
45

46
47 ORCID ID: 0009-0006-4584-7602
48
49

50
51 Amaia Bilbao-González, PhD ^{3, 9, 10,11}
52
53

54
55 ORCID ID: 0000-0002-2202-0753
56
57

58
59 Isabel del-Cura-González, PhD, MD ^{2,3,4,7,12}
60

ORCID ID: 0000-0002-3931-5304

- 1
2
3 1. Oeste Family and Community Care Teaching Unit, Primary Care Assistance
4
5 Management, Madrid Health Service, Madrid, Spain
6
- 7 2. Department of Medical Specialties and Public Health, Faculty of Health Sciences, Rey
8
9 Juan Carlos University, Madrid, Spain
10
- 11 3. Health Services Research Network in Chronic Diseases, REDISSEC-ISCIII, Research
12
13 Network on Chronicity, Primary Care and Health Promotion-RICAPPS (RICORS). ISCIII,
14
15 Spain
16
- 17 4. Gregorio Marañón Health Research Institute (IISGM), Madrid, Spain
18
- 19 5. Technical Directorate of Health Information Systems, Primary Care Management,
20
21 Madrid Health Service, Madrid, Spain
22
- 23 6. Doctoral student, Doctoral program in Health Sciences, Rey Juan Carlos University,
24
25 Madrid, Spain
26
- 27 7. Research Unit, Primary Care Assistance Management. Madrid Health Service, Madrid,
28
29 Spain
30
- 31 8. Infante Don Luis Health Centre, Primary Care Assistance Management, Madrid Health
32
33 Service, Madrid, Spain
34
- 35 9. Osakidetza Basque Health Service, Basurto University Hospital, Research and
36
37 Innovation Unit, Bilbao, Spain
38
- 39 10. Kronikgune Health Services Research Institute, Barakaldo, Spain
40
- 41 11. Department of Medicine, Faculty of Health Sciences, University of Deusto, Bilbao, Spain
42
- 43 12. Aging Research Centre. Department of Neurobiology, Care Sciences and Society.
44
45 Karolinska Institutet and Stockholm University. Stockholm, Sweden
46
47
48
49
50

51
52 *Corresponding author:

53
54
55 Jesús Martín-Fernández. UDMAFyC Oeste. C/ Alonso Cano 8, 28933 Móstoles, Madrid

56
57
58 Email: jmfernandez@salud.madrid.org
59
60

ABSTRACT:

Objective:

To examine whether socioeconomic status is associated with prognosis after the diagnosis of hypertension (HTN), in a population older than 65 years, in the community setting.

Design:

Retrospective cohort study.

Setting:

All the Primary Care Centres (PCC) of the Community of Madrid (n=392).

Participants:

All patients (> 65 years) with a new diagnosis of HTN in 2007-2008, without previous kidney or cardiovascular (K/CV) events (n=21,754).

Patient records from primary care Electronic Health Records (HER) and Spanish mortality database were analysed from January 2007 through December 2018. Sociodemographic data such as age, gender, area deprivation index the area (MEDEA -Mortalidad en áreas pequeñas Españolas y Desigualdades Socioeconómicas y Ambientales- index in quintiles), and characteristics, such as smoking, type 2 diabetes mellitus and hypercholesterolemia, were collected at the time of enrolment.

Primary and secondary outcome measures:

The occurrence of K/CV events (including mortality from these causes) and total mortality were evaluated using Cox regression.

Results:

1
2 Patients had a mean age of 73.5 (SD 6.5) years, and 63.5% were women. The median follow-up
3 was 128.7 months (IQR: 110.6-136.7 months). There were 10,648 first K/CV events, including
4 1,508 deaths from these causes and 4,273 deaths from other causes. Adjusted for age, gender,
5 smoking, diabetes and hypercholesterolemia, when comparing the third, fourth and last
6 quintiles (less affluent) of the deprivation index with respect to the first quintile, the hazard of
7 K/CV events increased by 14.8% (95%CI: 3.3-27.6%), 16.0% (95%CI: 6.4-26.4%) and 19.1%
8 (95%CI: 8.9-30.2%), respectively. The MEDEA index was not associated with differences in
9 adjusted total mortality.
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 Conclusion:

25
26
27 Living in a low socioeconomic status area is associated with an increase in kidney or
28 cardiovascular events in hypertensive patients diagnosed after age 65 years, which will result in
29 a significant increase in disease burden even if not related to an increase in total mortality.
30
31
32
33
34
35
36

37 Keywords: hypertension; socioeconomic factors; survival; ageing; primary care
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

The combination of mortality regional registries and "hard events" recorded in Electronic Health Records (EHRs) can be a powerful method for monitoring outcomes.

As elderly individuals may be more likely to have stable housing situations, the identification of socioeconomic level based on area of residence may be more plausible.

In 2018, the closing date of the study, 80% of the assigned population visited their family doctor on a PCC, which enhance study generalizability.

Some potential confounders as social support or individual socioeconomic variables have not been included.

The accuracy and completeness of registries in Electronic Health Records has been only validated for hypertension, diabetes mellitus, acute myocardial infarction and stroke diagnosis.

INTRODUCTION

Hypertension (HTN) is one of the most prevalent cardiovascular risk factors in the community environment, and the number of diagnoses has doubled in the past 30 years(1). HTN is associated with an excess of mortality, mainly mediated by cardiovascular (CV) disease(2,3). Although the control of hypertension through pharmacological and lifestyle measures has been shown to decrease mortality from these causes(4–7), it seems that hypertensive patients have an excess risk of cardiovascular events(8,9) and overall mortality(9–13). HTN is attributed to a large disease burden, making it responsible for the loss of 143 million disability-adjusted life years (DALYs) globally in 2015(3). Most of this burden of disease is due to cardiovascular and renal complications and mortality from these causes associated with the HTN diagnosis(14). However, neither the incidence of HTN nor its prognosis are homogeneous in all social groups. Almost two decades ago, potential associations between population characteristics and individual blood pressure figures began to emerge, and these figures were influenced by circumstances such as lower educational levels(15). Social deprivation in the place of residence was significantly associated with the appearance of hypertension, even after adjusting for demographic variables and lifestyles(16). Some studies showed that the probability of suffering HTN increased by up to 30% when comparing those who had spent their childhood among the most disadvantaged social classes with people who lived in advantaged areas(17). The association between socioeconomic status and HTN seems clear, and some authors proposed that it is strongly mediated by education level(18) and that the risk of HTN increases with age(19). Subsequently, it has been shown that a lower socioeconomic situation across the lifecourse was associated with a higher incidence of HTN and that both the accumulation of socioeconomic risks and the models of social mobility with more adverse socioeconomic trajectories increased the incidence rate of HTN(20,21).

The mechanisms that explain this association are not entirely clear. It seems that unhealthy lifestyles and other risk factors (e.g., smoking and obesity), which are more frequently found in

1
2
3 subjects from lower socioeconomic classes, could partly explain these relationships(17). In
4
5 studies carried out in our environment, it has been observed that the differences in the
6
7 prevalence of hypertension according to socioeconomic factors in an older population are small,
8
9 and it is suggested that, in women, the direct effect of socioeconomic status and level of
10
11 education on hypertension are negligible. However, in men education and socioeconomic status
12
13 are related to hypertension without being mediated by the usual risk factors(22).
14
15

16
17 More recent studies show that a higher number of social vulnerabilities are associated with a
18
19 progressively greater risk of developing HTN(23). The association of a lower socioeconomic
20
21 situation and the incidence of cardiovascular disease is well described(17,24). Additionally, it is
22
23 associated with higher mortality from these causes(25) and with total mortality. Inverse
24
25 association between educational level and cardiovascular mortality has been found in our
26
27 country and it was particularly strong among women(26). Some studies relate this inequity to
28
29 worse health care received by people with low socioeconomic status(27). However, it is not clear
30
31 whether patients with HTN in a setting with universal access to healthcare suffer from these
32
33 potential differences in their prognosis associated with socioeconomic situation.
34
35

36
37 The study of socioeconomic status can be approached from an individual or contextual
38
39 perspective. There are multiple characteristics that can define the socioeconomic situation,
40
41 which can be considered from a multidimensional perspective(28). Many of the studies
42
43 mentioned use indicators of individual socioeconomic status(23,25,29). Others use the
44
45 socioeconomic status of the area and evaluate its relationship with survival after a
46
47 cardiovascular event(30). In fact, the deprivation of the area has been shown to be a better
48
49 predictor than the individual socioeconomic situation when studying the occurrence of
50
51 cardiovascular events(31). In our setting, the MEDEA project (“Mortalidad en áreas pequeñas
52
53 Españolas y Desigualdades Socioeconómicas y Ambientales”) generated an area deprivation
54
55 index capable of detecting areas of low socioeconomic level, which has been shown to explain
56
57 differences in mortality(32). Addressing socioeconomic differences from a contextual
58
59
60

1
2 perspective has been successful in investigating differences in cardiovascular mortality due to
3 certain diseases(30).
4
5

6
7 In this framework, the evidence of the association between socioeconomic status and risk
8 factors for cardiovascular events was stronger in older subjects(19,25). Therefore, we aimed to
9 evaluate the potential association between the area-level socioeconomic status and the risk of
10 kidney and cardiovascular events and mortality after the diagnosis of HTN, in a population aged
11 65 and older in the community setting.
12
13
14
15
16
17
18
19
20
21
22

23 **Methods**

24
25 This is a retrospective observational study

26
27 We studied a cohort of all patients aged 65 years or older diagnosed with HTN without evidence
28 of kidney or cardiovascular disease at inclusion in their Electronic Health Record (EHR) in the
29 Primary Care Centres (PCC) of the Community of Madrid from January 1, 2007 to January 31,
30 2008. We used the code ICP-2 K86, which has been previously validated for the HTN
31 diagnosis(33). (Figure 1).
32
33
34
35
36
37
38
39

40 The exclusion criteria were being under 65 years of age, having suffered from kidney or
41 cardiovascular disease, having been diagnosed with hypertension or taking antihypertensive
42 medication, before the start of the observation period.
43
44
45
46
47

48 The follow-up lasted until December 31, 2018, or until the moment in which the patient died or
49 was discharged from the health records of the Autonomous Community.
50
51

52 Variables

53
54 Exposure variable: area socioeconomic status. The deprivation index assigned to each census
55 area in the MEDEA project is calculated from indicators related to work (unemployment, manual
56
57
58
59
60

1
2 and casual workers) and education (total insufficient education among young people)(32). The
3
4 index was categorized into quintiles, with the first being the most favoured and the fifth the
5
6 least favoured.
7
8

9 10 Covariates

11
12 Demographic and clinical variables were collected. Age at inclusion and gender were collected
13
14 from clinical records. The following clinical conditions were also collected as covariates: 1)
15
16 Diabetes mellitus type 2 (DM, ICPC-2 T89 and T90); 2) Smoking history (any review that the
17
18 patient smokes or diagnosis of active smoking- ICPC-2P17-at the time or in the year prior to
19
20 inclusion); 3) Hypercholesterolemia (ICPC-2 T93)
21
22

23
24 Age, gender and these three clinical conditions were recorded at the time of inclusion.
25
26

27 28 Outcome variables

29
30 In the follow-up, the following study outcomes were collected: 1) Kidney events: urinary
31
32 microalbuminuria (yes/no), defined as a urine albumin/creatinine ratio greater than 30,
33
34 existence of proteinuria (yes/no) defined as the presence of 300 mg/dl of protein in urine in at
35
36 least two consecutive samples in the absence of concomitant disease, or the presence of chronic
37
38 kidney disease (ICPC-2 U99.1); 2) CV events: ischaemic heart disease (acute myocardial
39
40 infarction- ICPC-2 K75, angina- ICPC-2K74-, cardiac ischaemia, chronic - ICPC-2 K76,
41
42 cerebrovascular disease- ICPC-2 K90, peripheral arterial disease- ICPC-2 K92; 3) Death from any
43
44 cause and kidney or CV death. deaths due to chronic kidney disease (ICD10: N18),
45
46 cerebrovascular accident (ICD10: G46; I60-I69), ischaemic heart disease (ICD10: I20-I25), heart
47
48 failure (ICD10: I50) and peripheral arterial disease (ICD10: I70, I71, I72, I74), were classified as
49
50 kidney/cardiovascular mortality.
51
52
53

54
55 For the definition of different diagnoses, the records of the Primary Care (PC) clinical history
56
57 were used and coded according to the International Classification of Primary Care (ICPC-2)(34).
58
59
60

1
2
3 The International Classification of Diseases 10th edition (ICD-10) was used to study the causes
4 of mortality (35).

5
6
7
8 The data sources linked using a matching algorithm were the EHR of PC and the registry of
9 mortality by specific cause of the National Institute of Statistics. This study followed the
10 guidelines for cohort studies, described in the Strengthening the Reporting of Observational
11 Studies in Epidemiology (STROBE) reporting guideline and the RECORD statement (Additional
12 file 1).

13 14 15 16 17 18 19 Analysis

20
21
22 The database construction involved several steps to enhance data quality (Figure 1).

23
24
25 The distribution of the independent variables of the subject, the mean area of residence and the
26 follow-up times were described.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Cox proportional hazards models were adjusted to study the risks associated with the context in which the subjects lived(36). The proportional hazards assumption in a Cox proportional hazards model was not met when using conventional tests, but hazard ratios over time were assessed and were found to be stable enough to proceed with the analysis. Additionally, other concerns such as influential outliers, missing data, or significant model misspecification were considered. The 95% confidence intervals for the Cox regression coefficients were estimated using bootstrap resampling. This approach has been suggested in large sample sizes or complex clinical scenarios(37).

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

The models were constructed including the MEDEA index as an independent variable and were adjusted for patient demographic and clinical variables. Two types of models were constructed. The first used the occurrence of kidney or cardiovascular events as the outcome, including mortality from these causes. In this model, follow-up was considered to end when the first of these events occurred, or when the subject was lost, or on 31 December 2018, whichever came first. The second type of models considered all-cause mortality as the event to be studied. The

1
2
3 final models were also built separately for men and women. Gender differences play an
4
5 influential role in multiple health-related outcomes. The importance of studying gender in
6
7 investigating the role of the cultural and social environment in the prognosis of HTN has been
8
9 highlighted(38).

10
11
12 Thee estimated size for the cohort of 20,000 subjects would allow finding differences in event
13
14 occurrences of 2% at 10 years in each of the deprivation index quintiles (between 12% and 20%)
15
16 even in the presence of very high variance inflation factors(39).

17
18
19 Stata 14.2[®] software was used for data analysis.

20 21 22 Patient and public involvement

23
24
25 None

26 27 28 **Results**

29
30
31 We included 21,754 patients over age 65 with new diagnoses of uncomplicated HTN in 392
32
33 centres and clinics: 12,335 in 2007 and 9,419 in 2008 (Figure 1).

34
35
36 Table 1 shows the characteristics of the studied cohort, in which women predominate (63.5%),
37
38 with a mean age at inclusion of 73.5 years (SD 6.5 years, range 65-101 years; median 72 years,
39
40 interquartile range 68-78 years).

41
42
43
44 The median follow-up of the cohort was 128.7 months (IQR 110.6-136.7 months).

Table 1. Characteristics of the studied cohort (n = 21,754)

Medea Index	1 st Q	2 nd Q	3 rd Q	4 th Q	5 th Q	Total*
Age						
65 to 74 years	2,562 (57.2%)	2,571 (59.2%)	2,655 (62.6%)	2,828 (64.7%)	2,797 (64.9%)	13,413 (61.7%)
75 to 84 years	1,503 (33.5%)	1,433 (33.0%)	1,301 (30.7%)	1,302 (29.8%)	1,304 (30.3%)	6,843 (31.5%)
≥ 85	417 (9.3%)	340 (7.8%)	283 (6.7%)	240 (5.5%)	207 (4.8%)	1,487 (6.8%)
Median (IQR)	73 (69-79)	73 (68-78)	72 (68-77)	72 (68-77)	72 (68-77)	72 (68-78)
Woman	3,000 (63.9%)	2,811 (64.7%)	2,666 (62.9%)	2,726 (62.4%)	2,598 (60.3%)	13,801 (63.5%)
Smokers	296 (6.6%)	272 (6.3%)	254 (6.0%)	268 (6.1%)	295 (6.9%)	1,385 (6.4%)
Diabetes mellitus	518 (11.6%)	569 (13.1%)	585 (13.8%)	685 (15.8%)	673 (15.6%)	3,030 (13.9%)
Hypercholesterolemia	1,221 (27.2%)	1,150 (26.51%)	1,168 (27.6%)	1,264 (28.9%)	1,240 (28.8%)	6,043 (27.8%)

*It was not possible to assign the MEDEA index to 11 subjects.

Q: quintile

IQR: Interquartile range

Occurrence of kidney or CV events included death from these causes

During follow-up, 10,648 first kidney/CV events occurred (including 1,508 deaths due to these causes without a previous event). A total of 1,937,655 person-months were observed, and the incidence rate of these events was 54/10,000 person-months. The median time of occurrence of the event was 62.6 months (IQR 33.6-92.3 months).

Table 2 shows the results of the best model explaining the association between the deprivation index and the occurrence of kidney/CV events (including death from these causes).

Table 2. Cox model for kidney or cardiovascular events, including mortality from these causes, adjusted for the covariates shown.

Variable	HR	HR 95%CI	<i>p</i> > <i>z</i>
Age			
75-84 vs. 65-74 years	1.767	1.686- 1.851	<0.001
≥ 85 vs. 65-74 years	2.980	2.731- 3.25	<0.001
Female vs. male	0.966	0.927- 1.006	0.097
Diabetes mellitus	1.357	1.283- 1.435	<0.001
Baseline smoking	1.208	1.122- 1.301	<0.001
Hypercholesterolemia	1.066	1.023- 1.111	0.002
Socioeconomic group			
2nd vs. 1st quintile	1.009	0.916- 1.112	0.849
3rd vs. 1st quintile	1.148	1.033- 1.276	0.010
4th vs. 1st quintile	1.160	1.064- 1.264	0.001
5th vs. 1st quintile	1.191	1.089- 1.302	<0.001
Included subjects = 21,743			
Number of clusters (centres): 392			
Number of events: 10,648			

HR = Hazard ratio; CI = Confidence interval

Adjusted for age, gender, smoking, diabetes mellitus and hypercholesterolemia, an association is observed between greater deprivation and the greater occurrence of kidney or CV events, starting from the third quintile of the MEDEA Index. This association increases slightly in intensity as the deprivation index worsens; the more unfavourable this index is, the stronger the association.

Figure 2 shows the cumulative hazard function by quintiles adjusted for the variables (at means) shown in the model in Table 2. The second quintile is not clearly different from the first, but there is an evident increase in cumulative hazard in the third, fourth and fifth quintiles, with respect to the first, after adjusting for the aforementioned variables.

1
2
3 The best model was run separately for men and women but no significant differences were
4 found with the overall model (see Additional file 2, Supplementary Tables).
5
6

7 Occurrence of mortality from any cause 8 9

10 During follow-up, 5,781 deaths occurred from any cause, 1,508 deaths from kidney/CV causes
11 and 4,273 from other causes. A total of 2,513,273 person-months was observed, and the
12 incidence rate of these events was 23/10,000 person-months. The median time to death in those
13 who died during the study period was 85.4 months (IQR 55.4–109.5 months).
14
15
16
17
18

19
20 The best model to study the association between the deprivation index and all-cause mortality
21 shows no association (Table 3). Regarding the adjustment variables, the association of age with
22 mortality was very strong; female sex and hypercholesterolemia were associated with lower
23 mortality, smoking and DM were associated with higher mortality.
24
25
26
27
28

29
30 Again, the best model for total mortality was run separately for men and women and no relevant
31 differences were found with the overall model (see Additional file 2, Supplementary Tables).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Cox model to explain all-cause mortality, adjusted for the covariates shown.

Variable	HR	HR CI 95%	<i>p</i> > z
Age			
75-84 vs. 65-74 years	3.446	3.255- 3.649	<0.001
≥ 85 vs. 65-74 years	13.115	12.214- 14.083	<0.001
Female vs. male	0.695	0.656- 0.736	<0.001
Diabetes mellitus	1.319	1.223- 1.422	<0.001
Baseline smoking	1.418	1.269- 1.583	<0.001
Hypercholesterolemia	0.782	0.731- 0.837	<0.001
Socioeconomic group			0.391
2nd vs. 1st quintile	0.942	0.82- 1.081	0.395
3rd vs. 1st quintile	0.913	0.798- 1.044	0.183
4th vs. 1st quintile	0.866	0.781- 1.006	0.062
5th vs. 1st quintile	0.952	0.846- 1.072	0.420
Included subjects = 21,743			
Number of clusters (centres): 392			
Number of events: 5,781			

HR = Hazard ratio; CI = Confidence interval

Discussion

The deprivation index of the area in which one lives is associated with an increase in kidney/CV events in hypertensive patients diagnosed after age 65 and without previous cardiovascular history, in follow-up in the community environment for more than 10 years. This association remained after adjusting for other potential demographic and metabolic risk factors, such as diabetes or hypercholesterolemia, or lifestyles indicators, such as smoking. This association was not found when mortality from all causes was studied. It should also be noted that no gender differences were found when studying the aforementioned relationships between socioeconomic status and prognosis in older patients with hypertension.

1
2
3 In this study, an increased hazard of almost 20% of kidney/CV events (including death due to
4 these causes) was found in patients residing in areas in the least affluent quintile compared to
5 those who inhabited the most favoured areas. The association between the incidence of HTN
6 and social group is already known(16,17), also in the elderly(22). In addition, an association
7 between a lower socioeconomic status and an increased risk of cardiovascular and total
8 mortality was found, and it seems that the factors that mediated this association had to do
9 mainly with habits and inflammatory markers rather than with psychosocial risk(25). Other
10 authors support that the role of conventional risk factors might be minor in explaining
11 relationship between social and psychological factors and cardiovascular disease(40). The
12 study of the association between socioeconomic status and mortality in hypertensive patients
13 has been recently reported at the individual level, but it was not evident when the
14 socioeconomic status of the area was studied (23). Suggested mechanisms to explain the
15 association between socioeconomic disadvantaged environments and cardiovascular disease
16 relate to dietary habits, physical activity resources and other cardiovascular risk factors(28). In
17 this paper we evaluated the association between area-level socioeconomic status and kidney
18 and cardiovascular events in hypertensive patients, adjusting for the effect of other risk factors
19 such as diabetes, smoking and hypercholesterolemia.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 We found no apparent relationship between the socioeconomic status of the area and total
42 mortality in newly diagnosed hypertensive patients over age 65 years. When the relationship
43 between socioeconomic status and total mortality in older patients is studied, the differences in
44 the Spanish population are lower than in the rest of Europe(41). These differences with respect
45 to patterns of other countries have been explained by lifestyles and the existence of stronger
46 social networks, regardless of social class. It has been mentioned how social support can be a
47 protective factor against cardiovascular mortality in older people(42). In our country, individuals
48 over age 65 who lived in provinces with the most adverse socioeconomic context had the highest
49 mortality from cardiovascular diseases and the lowest mortality from cancer and external
50
51
52
53
54
55
56
57
58
59
60

1
2
3 causes(43). This may mean that the association between socioeconomic status and total
4 mortality is not as strong as expected. In general, the trend of the past two decades is that
5 inequalities in total mortality reduced in all European countries and, especially, in Spain. This
6 change is attributed more to improvements in lifestyle and access to preventive activities than
7 to policies aimed at reducing health inequalities (44). A previous study conducted in the same
8 region as ours, reported a differential use of more intensive PC services in those subjects with
9 lower economic situations(45). This could indicate that there are no major problems with
10 accessibility to health care and preventive activities and would partly explain why no association
11 was found between the socioeconomic status of the area and total mortality in this group of
12 patients.
13
14
15
16
17
18
19
20
21
22
23
24

25 This study was subjected to several potential limitations. Given its design, causal inferences
26 cannot be made, individual socioeconomic variables have not been included, other variables
27 such as marital status have not been considered, underlying diseases have not been controlled,
28 and there are limitations inherent to studies that use registries not designed for research.
29 Among its potential strengths, this study points out that the monitoring of the outcomes could
30 be done exhaustively by combining two independent sources. We included all patients newly
31 diagnosed of HTN in two years in a region of Spain (Madrid) where more than 6 million people
32 live which resulted in a very large sample size and less concerns for selection bias as compared
33 to usual cohort studies or surveys. Since the study population is elderly, the identification of the
34 socioeconomic status with that of the area of residence may be more plausible. Also, the
35 generalizability of the results is good enough, as accessibility to the health system, specifically
36 to the PC doctor, is very high in our environment. In 2018, the closing date of the study, 80% of
37 the assigned population visited their family doctor on a PCC(46).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 The implications of the results discussed relate to practice, health policies and research. Firstly,
56 older patients diagnosed with hypertension in socioeconomic disadvantaged settings should be
57 monitored particularly closely. Secondly, as has been suggested, to reduce the burden of disease
58
59
60

1
2 derived from HTN, strategies are needed to accelerate the socioeconomic improvements of the
3 most vulnerable population and the development of environments that promote health (47).
4
5 Public health policies should focus on reducing social inequalities as a mechanism for improving
6
7 individual health, with special attention to elderly patients. Finally, these results encourage
8
9 further study of the role of social support, the cultural context of care and the health care system
10
11 in the prognosis of these diseases.
12
13
14
15
16
17
18
19

20 **Conclusion**

21
22 Living in a low socioeconomic status area is associated with an increase in kidney or CV events
23
24 in hypertensive patients diagnosed after the age of 65 years and with no previous cardiovascular
25
26 history, which will result in a significant increase in disease burden even if not related to an
27
28 increase in total mortality.
29
30

31
32 The role of access to health care and preventive activities should be established, as well as future
33
34 research on the lack of association between socioeconomic status and total mortality.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Declarations

Ethics approval and consent to participate

Authorization was obtained from the Ethics Committee at the Alcorcon Foundation University Teaching Hospital (18/115).

The study was carried out in accordance with the guidelines of good research practices, the principles of the Declaration of Helsinki (Fortaleza 2013), the provisions of Organic Law 3/2018 of December 5 for the Protection of Personal Data and guarantee of digital rights, and Law 14/2007 on Biomedical Research. Once all the databases were related, the data were dissociated, eliminating any potential identifiers.

The protocol approved by the Ethics Committee (see above) did not include a request for informed consent because the data handled by the researchers were dissociated and made patient identification impossible.

Consent for publication

Not applicable (see above)

Availability of data and materials

All data analysed in this study are available upon reasonable request to the research team.

Competing interests

The authors declare no conflicts of interest.

Funding

1
2 The study was funded by the Carlos III Health Institute (ISCIII, PI18/00370) and co-financed by
3 the European Union.
4

5
6
7 APCs have been funded by FIIBAP (Fundación para la Investigación e Innovación Biosanitaria en
8 Atención Primaria).
9

10 11 12 **Authors' contributions**

13
14
15
16 Conceived and designed the experiments: JMF, TAS, EPC, GRM, ABG.

17
18
19 Performed the experiments: JMF, TAS, EPC.

20
21
22 Analysed the data: JMF, TAS, PMG.

23
24
25 Discussed the results: JMF, TAS, PMG, EPC, GRM, ICG, ABG.

26
27
28 Wrote the manuscript: JMF, PMG, ICG.

29
30
31 Revised and approved the manuscript: JMF, TAS, PMG, EPC, GRM, ICG, ABG.

32
33
34 JMF and TAS assume the role of guarantors of the paper.

35
36
37 All authors read and approved the final manuscript.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet*. 2021;398(10304):957–80.
2. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. *BMJ* [Internet]. 1998 Jul 18;317(7152):167–71. Available from: <http://www.bmj.com/cgi/doi/10.1136/bmj.317.7152.167>
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015. *JAMA*. 2017;317(2):165–82.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338(7705):1245.
5. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. *Int J Cardiol* [Internet]. 2014 Sep;176(1):219–26. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0167527314012753>
6. Bundy J, Li C, Stuelik P, Bu X, Kelly T, Mills KT, et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality A Systematic Review and Network Meta-analysis. *JAMA Cardiol*. 2017;2(7):775–81.
7. Yun D, Lee H, Choi W, Chang H, Son D, Lee J. Association of optimal blood pressure with mortality in patients taking antihypertensive medications. *J Clin Hypertens* [Internet]. 2020 Nov 20;22(11):2035–43. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/jch.14034>
8. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension - A prospective cohort study over three decades. *J Intern Med*. 2005;257(6):496–502.
9. Martín-Fernández J, Alonso-Safont T, Polentinos-Castro E, Esteban-Vasallo MD, Ariza-

- 1
2
3 Cardiel G, González-Anglada MI, et al. Impact of hypertension diagnosis on morbidity
4 and mortality: a retrospective cohort study in primary care. *BMC Prim Care* [Internet].
5 2023 Mar 23;24(1):79. Available from: <https://doi.org/10.1186/s12875-023-02036-2>
6
7
8
9 10. Sepanlou SG, Sharafkhan M, Poustchi H, Malekzadeh MM, Etemadi A, Khademi H, et al.
10 Hypertension and mortality in the Golestan Cohort Study: A prospective study of 50000
11 adults in Iran [Internet]. Vol. 30, *J Hum Hypertens*. Macmillan Publishers Limited; 2016.
12 p. 260–7. Available from: <http://dx.doi.org/10.1038/jhh.2015.57>
13
14
15 11. da Silva TLN, Klein CH, Nogueira A da R, Salis LHA, de Souza E Silva NA, Bloch KV.
16 Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de
17 Janeiro - Brazil - 1991-2009. *BMC Public Health* [Internet]. 2015;15:623. Available from:
18 [http://www.mendeley.com/catalog/cardiovascular-mortality-among-cohort-](http://www.mendeley.com/catalog/cardiovascular-mortality-among-cohort-hypertensive-normotensives-rio-janeiro-brazil-19912009/)
19 [hypertensive-normotensives-rio-janeiro-brazil-19912009/](http://www.mendeley.com/catalog/cardiovascular-mortality-among-cohort-hypertensive-normotensives-rio-janeiro-brazil-19912009/)
20
21
22
23
24 12. Lawlor DA, Kim L, Morris R, Amuzu A, Whincup P, Ebrahim S. Survival with treated and
25 well-controlled blood pressure: Findings from a prospective cohort study. *PLoS One*.
26 2011;6(4).
27
28
29 13. Park S, Han K, Lee S, Kim Y, Lee Y, Kang MW, et al. Cardiovascular or mortality risk of
30 controlled hypertension and importance of physical activity. *Heart* [Internet]. 2021
31 Sep;107(18):1472–9. Available from:
32 <https://heart.bmj.com/lookup/doi/10.1136/heartjnl-2020-318193>
33
34
35
36 14. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol*
37 [Internet]. 2020 Apr 5;16(4):223–37. Available from:
38 <https://www.nature.com/articles/s41581-019-0244-2>
39
40
41
42 15. Merlo J, Asplund K, Lynch J, Rastam L, Dobson A. Population Effects on Individual
43 Systolic Blood Pressure: A Multilevel Analysis of the World Health Organization MONICA
44 Project. *Am J Epidemiol* [Internet]. 2004 Jun 15;159(12):1168–79. Available from:
45 <https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwh160>
46
47
48
49 16. Matheson FI, White HL, Moineddin R, Dunn JR, Glazier RH. Neighbourhood chronic
50 stress and gender inequalities in hypertension among Canadian adults: a multilevel
51 analysis. *J Epidemiol Community Heal* [Internet]. 2010 Aug 1;64(8):705–13. Available
52 from: <https://jech.bmj.com/lookup/doi/10.1136/jech.2008.083303>
53
54
55
56 17. Lawlor DA, Ebrahim S, Smith GD. Adverse socioeconomic position across the lifecourse
57 increases coronary heart disease risk cumulatively: Findings from the British women's
58
59
60

- heart and health study. *J Epidemiol Community Health*. 2005;59(9):785–93.
18. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension. *J Hypertens* [Internet]. 2015 Feb;33(2):221–9. Available from: <https://journals.lww.com/00004872-201502000-00004>
19. López-González ÁA, Bennasar-Veny M, Tauler P, Aguilo A, Tomàs-Salvà M, Yáñez A. Desigualdades socioeconómicas y diferencias según sexo y edad en los factores de riesgo cardiovascular. *Gac Sanit* [Internet]. 2015 Jan;29(1):27–36. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0213911114002350>
20. Lopes JAS, Giatti L, Griep RH, Lopes AADS, Matos SMA, Chor D, et al. Life Course Socioeconomic Position, Intergenerational Social Mobility, and Hypertension Incidence in ELSA-Brasil. *Am J Hypertens* [Internet]. 2021 Aug 9;34(8):801–9. Available from: <https://academic.oup.com/ajh/article/34/8/801/6129314>
21. Duarte C d. P, Wannier SR, Cohen AK, Glymour MM, Ream RK, Yen IH, et al. Lifecourse Educational Trajectories and Hypertension in Midlife: An Application of Sequence Analysis. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2022;77(2):383–91.
22. Regidor E, Gutiérrez-Fisac JL, Banegas JR, Domínguez V, Rodríguez-Artalejo F. Association of adult socioeconomic position with hypertension in older people. *J Epidemiol Community Health* [Internet]. 2006 Jan 1;60(1):74–80. Available from: <https://jech.bmj.com/lookup/doi/10.1136/jech.2005.038331>
23. King JB, Pinheiro LC, Bryan Ringel J, Bress AP, Shimbo D, Muntner P, et al. Multiple Social Vulnerabilities to Health Disparities and Hypertension and Death in the REGARDS Study. *Hypertension* [Internet]. 2022 Jan;79(1):196–206. Available from: <https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15196>
24. Woodward M, Peters SAE, Batty GD, Ueshima H, Woo J, Giles GG, et al. Socioeconomic status in relation to cardiovascular disease and cause-specific mortality: a comparison of Asian and Australasian populations in a pooled analysis. *BMJ Open* [Internet]. 2015 Mar 17;5(3):e006408–e006408. Available from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2014-006408>
25. Stringhini S, Zaninotto P, Kumari M, Kivimäki M, Lassale C, Batty GD. Socio-economic trajectories and cardiovascular disease mortality in older people: The English Longitudinal Study of Ageing. *Int J Epidemiol*. 2018;47(1):36–46.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26. Haeberer M, León-Gómez I, Pérez-Gómez B, Tellez-Plaza M, Rodríguez-Artalejo F, Galán I. Social inequalities in cardiovascular mortality in Spain from an intersectional perspective. *Rev Española Cardiol (English Ed [Internet]*. 2020 Apr;73(4):282–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1885585719303391>
 27. Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *Lancet Glob Heal [Internet]*. 2019 Jun;7(6):e748–60. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2214109X19300452>
 28. Havranek EP, Mujahid MS, Barr DA, Blair I V., Cohen MS, Cruz-Flores S, et al. Social determinants of risk and outcomes for cardiovascular disease: A scientific statement from the American Heart Association. *Circulation*. 2015;132(9):873–98.
 29. Andersson T, Pikkemaat M, Schiöler L, Hjerpe P, Carlsson AC, Wändell P, et al. The impact of diabetes, education and income on mortality and cardiovascular events in hypertensive patients: A cohort study from the Swedish Primary Care Cardiovascular Database (SPCCD). Pizzi C, editor. *PLoS One [Internet]*. 2020 Aug 3;15(8):e0237107. Available from: <https://dx.plos.org/10.1371/journal.pone.0237107>
 30. Chaix B, Rosvall M, Merlo J. Neighborhood Socioeconomic Deprivation and Residential Instability. *Epidemiology [Internet]*. 2007 Jan;18(1):104–11. Available from: <http://journals.lww.com/00001648-200701000-00017>
 31. Leyland AH. Socioeconomic gradients in the prevalence of cardiovascular disease in Scotland: The roles of composition and context. *J Epidemiol Community Health*. 2005;59(9):799–803.
 32. Domínguez-Berjón MF, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarín MI, et al. Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA). *Gac Sanit*. 2008;22(3):179–87.
 33. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, Soto-Díaz S, Fuentes-Rodríguez CY, Abánades-Herranz JC, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. *BMC Med Res Methodol [Internet]*. 2011 Dec 28;11(1):146. Available from: <http://bmcmmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-11-146>
 34. World Health Organization (WHO). International Classification of Primary Care, -ICPC-2.

- World Health Organization; 2009.
35. World Health Organization (WHO). ICD-10: international statistical classification of diseases and related health problems: tenth revision. World Health Organization; 2004.
36. Christensen E. Multivariate survival analysis using Cox's regression model. *Hepatology* [Internet]. 1987 Nov;7(6):1346–58. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/hep.1840070628>
37. Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? *JAMA* [Internet]. 2020 Apr 14;323(14):1401. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2763185>
38. Azizi Z, Alipour P, Raparelli V, Norris CM, Pilote L. The role of sex and gender in hypertension. *J Hum Hypertens* [Internet]. 2022 Dec 12;37(8):589–95. Available from: <https://www.nature.com/articles/s41371-022-00789-4>
39. Ahnn S, Anderson SJ. Sample size determination for comparing more than two survival distributions. *Stat Med* [Internet]. 1995 Oct 30;14(20):2273–82. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.4780142010>
40. Tillmann T, Pikhart H, Peasey A, Kubinova R, Pajak A, Tamosiunas A, et al. Psychosocial and socioeconomic determinants of cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. Rahimi K, editor. *PLOS Med* [Internet]. 2017 Dec 6;14(12):e1002459. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L620054900%0Ahttp://dx.doi.org/10.1371/journal.pmed.1002459>
41. Regidor E, Kunst AE, Rodríguez-Artalejo F, Mackenbach JP. Small socio-economic differences in mortality in Spanish older people. *Eur J Public Health* [Internet]. 2012 Feb;22(1):80–5. Available from: <https://academic.oup.com/eurpub/article-lookup/doi/10.1093/eurpub/ckr051>
42. Ramsay S, Ebrahim S, Whincup P, Papacosta O, Morris R, Lennon L, et al. Social Engagement and the Risk of Cardiovascular Disease Mortality: Results of a Prospective Population-Based Study of Older Men. *Ann Epidemiol* [Internet]. 2008 Jun;18(6):476–83. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1047279708000082>
43. Regidor E, Vallejo F, Reques L, Cea L, Miqueleiz E, Barrio G. Area-level socioeconomic context, total mortality and cause-specific mortality in Spain: Heterogeneous findings

- 1
2 depending on the level of geographic aggregation. Soc Sci Med [Internet]. 2015
3 Sep;141:142–50. Available from: <http://dx.doi.org/10.1016/j.socscimed.2015.07.030>
4
5
6
7 44. Mackenbach JP, Kulhánová I, Artnik B, Bopp M, Borrell C, Clemens T, et al. Changes in
8 mortality inequalities over two decades: register based study of European countries.
9 BMJ [Internet]. 2016 Apr 11;353:i1732. Available from:
10 <https://www.bmj.com/lookup/doi/10.1136/bmj.i1732>
11
12
13
14 45. Martín-Fernández J, Gómez-Gascón T, Cura-González MI Del, Tomás-García N, Vargas-
15 Machuca C, Rodríguez-Martínez G. [Quality of life related to health as a factor
16 explaining the use of family medical consultation: a study on the behavioral model]. Rev
17 Esp Salud Publica [Internet]. 2010;84(3):293–19. Available from:
18 <http://www.ncbi.nlm.nih.gov/pubmed/20661529>
19
20
21
22
23 46. Servicio Madrileño de Salud. Consejería de Sanidad. Indicadores de Atención Primaria
24 [Internet]. Observatorio de resultados del Servicio Madrileño de Salud. 2021. Available
25 from:
26 <http://observatorioresultados.sanidadmadrid.org/AtencionPrimariaFicha.aspx?ID=73>
27
28
29
30 47. O'Brien E. The Lancet Commission on hypertension: Addressing the global burden of
31 raised blood pressure on current and future generations. J Clin Hypertens.
32 2017;19(6):564–8.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Cohort generation flow diagram**
4
5
6
7
8
9
10

11
12 EHR: Electronic Health Record; CIBELES: Centre of strategic basic information for health
13 environments
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

1
2
3 **Figure 2. Cumulative hazard function of suffering a kidney or cardiovascular event (including**
4 **death from these causes) according to MEDEA quintile, adjusted for age, gender, presence of**
5 **diabetes mellitus, smoking and hypercholesterolemia (model in table 2).**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enregistrement Supérieur (ABES).



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

We agree with the reviewer that these calculations may no longer be necessary. The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found		RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and time and place within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 1,3 Page 3 Page 3
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Page 6-7
Objectives	3	State specific objectives, including any prespecified hypotheses			Page 8
Study Design					
Study Design	4	Present key elements of study design early in the paper			Page 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Page 7-8

086/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (A.B.E.S.). All rights reserved. No reuse allowed without permission.

<p>Participants</p>	<p>6</p>	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation is conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Page 8 & Figure 1</p> <p>Page 9</p> <p>Page 9-10 & Figure 1</p>
<p>Variables</p>	<p>7</p>	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>		<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported an explanation should be provided.</p>	<p>Page 8-9</p>
<p>Data sources/ measurement</p>	<p>8</p>	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p>			

38/bmjopen-2023-075188 on 29 August 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur TA-BE-S. All rights reserved. No reuse allowed without permission.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Bias	9	Describe any efforts to address potential sources of bias			Page 8,9,10
Study size	10	Explain how the study size was arrived at			Page 11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why			Page 10, 11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses			Page 10, 11
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Page 10; Declarations

086/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025
 Enregistrement Supérieur (ABES) .
 Agence Bibliographique de l'Enseignement Supérieur (ABES) .
 Acted by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Page 10
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Page 8, 9, 10
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	(c)	RECORD 13.1: Describe in detail the selection of the persons included in the study (i.e., study population) including filtering based on data quality, data availability, and data linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Figure 1
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (e.g., average and total amount)			(a) Page 11, Table 1 (c) Page 11
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure			Page 12-14 Table 2, 3 Figure 2

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			Page 12-14 Table 2,3, Figure 2
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses			Non applicable
Discussion					
Key results	18	Summarise key results with reference to study objectives			Page 15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Page 17
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			Page 16-18

36/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). All rights reserved. No reuse allowed without permission.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results			Page 17
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based			Page 20
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Additional file 2

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langlois SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

86/bmjopen-2023-075188 on 29 August 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (A.B.E.S.) - Université de Lille. All rights reserved.

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplementary tables

Table 1. Cox model for kidney and cardiovascular events, including mortality from these causes, adjusted for the covariates shown (only men)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	1.656	1.542- 1.779	<0.001
≥ 85 vs. 65-74 years	2.639	2.262- 3.078	<0.001
Diabetes mellitus	1.335	1.234- 1.445	<0.001
Baseline smoking	1.219	1.111- 1.337	<0.001
Hypercholesterolemia	1.072	0.994- 1.157	0.065
Socioeconomic group			0.018
2nd vs. 1st quintile	1.082	0.958- 1.222	0.206
3rd vs. 1st quintile	1.141	1.007- 1.294	0.039
4th vs. 1st quintile	1.142	1.019- 1.28	0.022
5th vs. 1st quintile	1.213	1.078- 1.366	0.001
Characteristics of the model: No. of subjects = 7,942, number of clusters (centres): 392, Number of events: 3,852			

Table 2. Cox model for kidney and cardiovascular events, including mortality from these causes, adjusted for the covariates shown (only women)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	1.830	1.728- 1.937	<0.001
≥ 85 vs. 65-74 years	3.121	2.816- 3.459	<0.001
Diabetes mellitus	1.372	1.281- 1.469	<0.001
Baseline smoking	1.161	1.015- 1.327	0.029
Hypercholesterolemia	1.064	1.012- 1.119	0.018
Socioeconomic group			<0.001
2nd vs. 1st quintile	0.972	0.873- 1.082	0.601
3rd vs. 1st quintile	1.151	1.027- 1.29	0.016
4th vs. 1st quintile	1.171	1.062- 1.291	0.001
5th vs. 1st quintile	1.176	1.06- 1.304	0.002
Characteristics of the model: No. of subjects = 13,801, number of clusters (centres): 392, Number of events: 6,791.			

Table 3. Cox model for total mortality, adjusted for the covariates shown (only men)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	2.897	2.657- 3.159	<0.001
≥ 85 vs. 65-74 years	9.861	8.648- 1.125	<0.001
Diabetes mellitus	1.264	1.127- 1.419	<0.001
Baseline smoking	1.380	1.221- 1.56	<0.001
Hypercholesterolemia	0.791	0.713- 0.877	<0.001
Socioeconomic group			0.462
2nd vs. 1st quintile	0.892	0.755- 1.053	0.177
3rd vs. 1st quintile	0.919	0.783- 1.079	0.304
4th vs. 1st quintile	0.915	0.78- 1.073	0.273
5th vs. 1st quintile	0.994	0.854- 1.158	0.942
Characteristics of the model: No. of subjects = 7,942, number of clusters (centres): 392, Number of events: 2,349.			

Table 4. Cox model for total mortality, adjusted for the covariates shown (only women)

Variable	HR	HR CI 95%	p> z
Age			
75-84 vs. 65-74 years	4.056	3.723- 4.419	<0.001
≥ 85 vs. 65-74 years	15.814	14.433- 17.327	<0.001
Diabetes mellitus	1.361	1.234- 1.501	<0.001
Baseline smoking	1.378	1.133- 1.676	0.001
Hypercholesterolemia	0.786	0.726- 0.85	<0.001
Socioeconomic group			0.388
2nd vs. 1st quintile	0.982	0.838- 1.149	0.819
3rd vs. 1st quintile	0.909	0.776- 1.065	0.237
4th vs. 1st quintile	0.872	0.749- 1.016	0.079
5th vs. 1st quintile	0.917	0.799- 1.052	0.217
Characteristics of the model: No. of subjects = 13,801, number of clusters (centres): 392, Number of events: 3,429.			